

MY REASON WHY

The power of EPKINLY makes remission possible

For diffuse large B-cell lymphoma (DLBCL) that returned or didn't respond after 2 or more prior treatments.

In a clinical study of 148 patients, EPKINLY achieved remission in 61% (90 patients): complete remission in 38% (56 patients) and partial remission in 23% (34 patients).

EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY.



Actor portrayals.

WHAT IS EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening.
- **Neurologic problems** that can be life-threatening and lead to death.
- **Infections and Low blood cell counts.**

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).




Learn about EPKINLY and what to expect from treatment

What's inside

How EPKINLY works	4
Results with EPKINLY	6
How EPKINLY injections are given	8
Important Safety Information	10
Resources and support for you and your care partner . . .	12
Tips for talking to your healthcare provider	14
EPKINLY Treatment Tracker	16
Appointment calendar.....	18
EPKINLY discussion guide	24

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


 epcoritamab-byspTM
 SUBCUTANEOUS INJECTION 4mg|48mg



It's time for a different kind of treatment

When you find out that your cancer has come back or hasn't responded after 2 or more types of treatment, you may be wondering what's next. Remission is still possible, and you have another option—a treatment that you can start when you're ready.

EPKINLY is a different kind of treatment:

- It's a bispecific antibody treatment for DLBCL that is given as a subcutaneous injection, which means it's given under the skin
- It's a treatment that harnesses the power of your own immune system to help fight cancer
- It's given as an injection when you need to start treatment. It is not an infusion or chemotherapy

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).

Visit [EPKINLY.com](https://www.epkinly.com) to discover what EPKINLY can mean for you.


epkinly[™]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

MY REASON WHY

EPKINLY harnesses the power of my own immune system

EPKINLY is the first-of-its-kind bispecific antibody treatment for certain types of DLBCL that returned or didn't respond after 2 or more prior treatments

EPKINLY is different from chemotherapy or stem cell therapy. It is a bispecific antibody that works by harnessing the power of your own immune system to fight cancer.

SELECT IMPORTANT SAFETY INFORMATION

Because EPKINLY works with your immune system it **can cause serious side effects, including cytokine release syndrome (CRS), neurologic problems**, infections, and low blood cell counts.


EPKINLY is designed to target 2 types of cells in your body— T cells and B cells.

- T cells are immune cells that fight infections, as well as cancer cells
- B cells are another type of immune cell, and in DLBCL, some B cells can become cancerous and grow uncontrollably

EPKINLY works by attaching to both your T cells and B cells, binding them together so that the T cells can attack and destroy B cells.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



SELECT IMPORTANT SAFETY INFORMATION

Because EPKINLY works with your immune system **it can cause serious side effects, including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts.**

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epcoritamab-bysp[™]
SUBCUTANEOUS INJECTION 4mg/48mg

Remission is possible

EPKINLY delivers powerful efficacy that can transform uncertainty into hope

The goal of EPKINLY is to help you achieve long-term remission. Learn about the results that were seen in the clinical study with EPKINLY.

EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY.

61%

Complete or partial remission

EPKINLY helped 61% of patients (90 of 148) achieve complete or partial remission (signs of cancer either disappeared or decreased)

38%

Complete remission

EPKINLY helped 38% of patients (56 of 148) achieve complete remission (signs of cancer disappeared completely)

23%

Partial remission

EPKINLY helped 23% of patients (34 of 148) achieve partial remission (signs of cancer decreased)

15.6 months

Of the 90 patients who achieved complete or partial remission, half were **still responding to EPKINLY** for at least 15.6 months

SELECT IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you may receive other medicines before receiving EPKINLY and you will also be given smaller doses of EPKINLY for the first 2 doses (called “step-up” dosing). Your first full dose will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide at EPKINLYMedGuide.com](#).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

~6
WEEKS

Patients who achieved complete or partial remission **started seeing results in as little as 6 weeks** on treatment with EPKINLY.*

*Median[†] of 1.4 months. Range 1 to 8.4 months.

[†]The median is the number that is exactly in the middle of range seen in the study.

SELECT IMPORTANT SAFETY INFORMATION

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems. Do not** drive or use heavy machinery or do other dangerous activities if you have any symptoms that impair consciousness until your symptoms go away.

Your healthcare provider will monitor you for symptoms of CRS, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).



How was EPKINLY studied?

EPKINLY was studied in 148 patients with DLBCL who had 2 or more treatments and whose cancer returned or did not respond.

Patients had been through a median[†] of 3 different types of treatments (range of prior treatments was 2 to 11), such as chemotherapy, immunotherapy (uses your body's immune system to help fight cancer), stem cell transplant, and CAR T therapy (chimeric antigen receptor T cell).



epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

MY REASON WHY

Unlike an infusion that may take time to administer, EPKINLY is given as an injection

You may receive treatment at a nearby outpatient center that is able to administer EPKINLY

EPKINLY dosing schedule



EPKINLY uses a “step-up dosing schedule.”

During the first 2 weeks of treatment, you will receive smaller “step-up” doses than the doses you will receive in week 3 and for the rest of your treatment.

Important things to know:

- If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule
- The step-up dosing schedule is designed to increase tolerability and help limit the potential for, and severity of, CRS
- Your healthcare provider will discuss with you the need to be hospitalized for 24 hours after your first full dose of EPKINLY (week 3/3rd dose) due to the risk of CRS and neurologic problems
- You may have side effects during treatment. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects
- Before each dose of EPKINLY in your first 4 weeks of treatment, you will receive other medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS in later doses of EPKINLY

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- Infections that may lead to death. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

Staying on treatment with EPKINLY may help you achieve remission and continue to see response

Ongoing treatment with EPKINLY ensures that the medicine continues to work in your body to help you maintain remission.

- You will receive EPKINLY for as long as your healthcare provider finds it is working for you and your side effects are manageable
- Your healthcare provider may delay or completely stop your treatment with EPKINLY if you have certain side effects



SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- **Low blood cell counts** are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.
- Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Keep track of your injections and how you're feeling in the [Treatment Tracker](#) on page 16.


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

Important Safety Information

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you may receive other medicines before receiving EPKINLY and you will also be given smaller doses of EPKINLY for the first 2 doses (called “step-up” dosing). Your first full dose of EPKINLY will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious;

headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems. Do not** drive or use heavy machinery or do other dangerous activities if you have any symptoms that impair consciousness until your symptoms go away.

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts** are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Please see additional Important Safety Information on page 11.
Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

Important Safety Information (continued)

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant,** your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).



Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems on page 10. Please see Medication Guide at EPKINLYMedGuide.com.


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg

MyNavCare™ is here to support you



With *MyNavCare*, you can receive personalized support throughout your treatment journey from a dedicated team that cares.



A partner on your treatment journey

Your healthcare provider is your main source for treatment information. With *MyNavCare*, you gain access to additional resources and medication information.

- Dedicated support throughout your treatment
- Information about treatment access and financial support*
- Insight into independent organizations that may provide additional assistance
- Additional tools and resources that may help along the way



Financial assistance for eligible patients

MyNavCare may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:

- Co-pay assistance program for commercially insured patients*
- Independent patient assistant foundation information†
- Genmab Patient Assistance Program



Ongoing personalized support

Your **Patient Engagement Liaison** is an experienced nurse and trained in treatment support.‡ They're dedicated to you, helping to:

- Provide information about your condition
- Connect you to external organizations
- Offer resources for you and your care partners

*Based on eligibility requirements and Terms and Conditions.

†Eligibility criteria is determined by each independent third-party foundation. *MyNavCare* does not determine eligibility and cannot guarantee foundations will offer assistance.

‡Patient Engagement Liaisons are provided by *MyNavCare* Patient Support and do not work under the direction of your doctor or provide medical advice. Patients should speak with their doctor about any treatment-related questions.

Contact a *MyNavCare* Support Specialist by calling
1-866-NAV-CARI (1-866-628-2271), Monday-Friday, 8 AM-8 PM ET.
Or visit [MyNavCare.com](https://www.mynavcare.com) to learn more.



Information for care partners

If you're a care partner, you play an important role and have become an integral part of your loved one's healthcare team.

These are some of the roles you may need to take on during your loved one's treatment:

- **Medical:** Helping them understand treatment decisions, scheduling appointments, and monitoring side effects
- **Logistical:** Managing their insurance, driving them to appointments, and running errands to give them more time to focus on remission
- **Emotional:** Encouraging them to share their feelings and helping them with treatment questions so they feel supported

Care for care partners

Being a care partner is an important and meaningful role that can be very rewarding. But it's important to take care of yourself and your own well-being, too.

Staying active, staying hydrated, and getting enough sleep can help you stay physically healthy. When you feel overwhelmed, find ways to manage stress, whether it's going for a walk, meditating, or talking to a friend. Also, it's okay to ask for help when you need a break to take time for yourself. Remember, there is support available.

Resources and support for you and your care partner

There are many other resources and tools that can provide support for you and your care partner. The following are some organizations that can help you and your care partner connect with others like you, as well as provide information and tips throughout your treatment.



LEUKEMIA &
LYMPHOMA
SOCIETY*

The Leukemia & Lymphoma Society

www.lls.org | 800-955-4572



Lymphoma Research Foundation

www.lymphoma.org | 800-500-9976



American
Cancer
Society

American Cancer Society

www.cancer.org | 800-227-2345



CANCERCARE

CancerCare

www.cancercare.org
800-813-HOPE (4673)



Family
Reach

Family Reach

www.familyreach.org
973-394-1411 ext. 1



Patient Advocate
Foundation

Patient Advocate Foundation

www.patientadvocate.org
800-532-5274

There are many available resources that may be helpful to patients, families, and care partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab/AbbVie is not responsible for their content.



CONSIDERING EPKINLY

Talk to your healthcare provider to see if EPKINLY is right for you

If you are considering treatment with EPKINLY, this tool can help you prepare for your appointment. It includes some questions you may wish to ask your healthcare provider, along with other tools that can help make the most of your appointment.

My treatments

These are the treatments I have received:

CAR T therapy

Stem cell transplant

Chemoimmunotherapy (eg, R-CHOP)

Other _____

Use this chart to write notes about your previous treatments so you can discuss them with your healthcare provider. Write down what you experienced with each treatment.

Type of treatment	What was your experience with this treatment? (eg, how you responded, side effects, dosing, how it was given)

My treatment goals

Write down your treatment goals and share them with your healthcare provider.

My current medications

List all your current medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide at EpkinlyMedGuide.com.


 epcoritamab-bysp™
 SUBCUTANEOUS INJECTION 4mg/48mg

Questions about EPKINLY

Is EPKINLY right for me?

How is EPKINLY different from other treatments?

Is remission possible with EPKINLY?

How will I receive EPKINLY?

Notes and/or additional questions

Use this chart to take notes when discussing EPKINLY with your healthcare provider.

EPKINLY	Notes
How it works	
Potential treatment benefits	
How it is given	
Potential treatment risks	

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](http://EPKINLYMedGuide.com) at EPKINLYMedGuide.com.


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg|48mg



JUST STARTING/CURRENTLY TAKING EPKINLY

EPKINLY Treatment Tracker

As you continue treatment, it's important to keep track of how you're feeling and what you may be experiencing in between your appointments. Be sure to discuss these with your healthcare provider.

DOSE 1 Date: / /

How I'm feeling: _____

Next appointment date: _____

Questions for my healthcare team: _____

DOSE 2 Date: / /

How I'm feeling: _____

Next appointment date: _____

Questions for my healthcare team: _____

DOSE 3 Date: / /

How I'm feeling: _____

Next appointment date: _____

Questions for my healthcare team: _____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide at EPKINLYMedGuide.com.


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

DOSE 4 Date: / /

How I'm feeling: _____

Next appointment date: _____

Questions for my healthcare team: _____

DOSE 5 Date: / /

How I'm feeling: _____

Next appointment date: _____

Questions for my healthcare team: _____

DOSE 6 Date: / /

How I'm feeling: _____

Next appointment date: _____

Questions for my healthcare team: _____

DOSE 7 Date: / /

How I'm feeling: _____

Next appointment date: _____

Questions for my healthcare team: _____

This tracker helps you track 7 doses of EPKINLY. Please continue to track for as long as you receive the treatment. Call your healthcare provider for medical advice about any side effects that you are experiencing.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide at EPKINLYMedGuide.com.





Appointment calendar

Use this calendar to keep track of all your appointments associated with EPKINLY treatment. Make notes here prior to the appointment if you have questions for your healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Appointment calendar

Use this calendar to keep track of all your appointments associated with EPKINLY treatment. Make notes here prior to the appointment if you have questions for your healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Appointment calendar

Use this calendar to keep track of all your appointments associated with EPKINLY treatment. Make notes here prior to the appointment if you have questions for your healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](http://EPKINLYMedGuide.com) at EPKINLYMedGuide.com.


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Appointment calendar

Use this calendar to keep track of all your appointments associated with EPKINLY treatment. Make notes here prior to the appointment if you have questions for your healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](http://EPKINLYMedGuide.com) at EPKINLYMedGuide.com.


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Appointment calendar

Use this calendar to keep track of all your appointments associated with EPKINLY treatment. Make notes here prior to the appointment if you have questions for your healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Appointment calendar

Use this calendar to keep track of all your appointments associated with EPKINLY treatment. Make notes here prior to the appointment if you have questions for your healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



EPKINLY discussion guide

This tool can help you communicate with your healthcare team as you continue your treatment with EPKINLY. It includes some questions you may wish to ask your healthcare provider. Don't forget to use the space here to take notes during your appointment.

Questions to ask your healthcare provider during treatment

Check off the boxes of questions you would like to ask. Your treatment journal will help guide discussions with your healthcare provider. Use these tools and the space provided to add any additional questions you may have.

Is there anything else I need to be aware of while I am receiving EPKINLY?

Where will I be given my first full dose of EPKINLY?

Is there anything more I can do to make my overall health better during treatment?

What tests will I need during treatment?

Are there other resources that can help me manage any side effects during treatment?

Am I reaching my treatment goals?

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epcoritamab-byspTM
SUBCUTANEOUS INJECTION 4mg/48mg



Important contact information

Stay on top of all the information that you are receiving from your healthcare team. Capture any important information or questions you may have to discuss with your healthcare provider.

Use this space to take note of your healthcare information, as well as contact information for your doctor, nurse, pharmacy, and/or emergency contact.

My Doctor

Name: _____

Phone number: _____

Office address: _____

My Nurse

Name: _____

Phone number: _____

Office address: _____

My Pharmacy

Name: _____

Phone number: _____

Office address: _____

My Emergency Contact

Name: _____

Phone number: _____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide at EPKINLYMedGuide.com](http://EPKINLYMedGuide.com).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

Notes

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide at EPKINLYMedGuide.com.





What's your reason?

Talk to your healthcare provider about EPKINLY

Visit [EPKINLY.com](https://www.epkinly.com) for more information.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).



Distributed and marketed by Genmab US, Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536.
Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.
EPKINLY and *MyNavCare* are trademarks of Genmab A/S. All other trademarks and registered trademarks are the property of their respective owners.
©2023 Genmab A/S and AbbVie. All rights reserved.
11/2023 COM-US-EPK-0000418


epkinly[™]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg